Description: Altimmune,Inc., formerly Pharmathene, Inc., is a biodefense company. The Company is focused on the development of medical counter measures against biological and chemical threats. The Company is involved in the development of two next generation anthrax vaccines. The Company's anthrax vaccines use recombinant protective antigen (rPA) manufacturing processes. The Company's product portfolio includes recombinant butyrylcholinesterase (rBChE) bioscavenger, which is used in prevention and treatment of nerve agent poisoning. The Company has developed a recombinant form of human butyrylcholinesterase for pre- and post-exposure therapy to patients with nerve agent attacks. Its rBChE bioscavenger acts with mechanism, which includes reversal of the acute toxicity associated with organophosphate poisoning agents used in chemical warfare (cholinergic crisis). Its development program also includes Valortim for monoclonal human antibody treatment.
Home Page: altimmune.com
ALT Technical Analysis
910 Clopper Road
Gaithersburg,
MD
20878
United States
Phone:
240 654 1450
Officers
| Name | Title |
|---|---|
| Dr. Vipin K. Garg Ph.D. | Pres, CEO & Director |
| Mr. Richard I. Eisenstadt M.B.A. | Chief Financial Officer |
| Dr. M. Scot Roberts Ph.D. | Chief Scientific Officer |
| Dr. Matthew Scott Harris AGAF, FCAP, M.D., MS | Chief Medical Officer |
| Mr. Bertrand Georges Ph.D. | Chief Technology Officer |
| Mr. Tony Blandin B.S. | VP of Quality & Compliance Management |
| Mr. José Ochoa | Chief Bus. Officer |
| Mr. Kent A. Tapper BSEE | Corp. Controller |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.5847 |
| Price-to-Sales TTM: | 162.9822 |
| IPO Date: | 2005-10-06 |
| Fiscal Year End: | December |
| Full Time Employees: | 47 |